Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-41.48M |
| Operating Margin | 0.00% |
| Return on Equity | -34.20% |
| Return on Assets | -20.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.59 |
| Price-to-Book | 3.42 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.19M |
| Float | $57.13M |
| % Insiders | 17.13% |
| % Institutions | 58.46% |
Volatility is currently contracting
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY.
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses.
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws. On July 20, 2026, Immix disclosed that it had terminated its Chief Medical Officer (“CMO”) following multiple news reports that the CMO had been using a false identity and was a recently captured fugitive. The price of the Company's stock dropped following this news.
Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma") (NASDAQ: IMMX).
BOSTON, July 20, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Immix Biopharma (Nasdaq: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMMX and any ticker you trade — then tracks every position and per-strategy win rate.
